Extedo adds two to management board

Directors will be based in Germany and US respectively

Extedo, a provider of eRegulatory Affairs solutions to life sciences firms, has added Martin Schmid and Joseph Dude to its management board.

Schmid joins the organisation as president and now shares day-to-day operational responsibilities with chief executive Tore Bergsteiner.

Dude has taken the position of managing director at Extedo Inc in the US, to support the organisation’s expansion in North America.

Schmid will head up the global marketing and sales organisation as well as the Product Management Unit, which are key areas for Extedo. He will be based in Ottobrunn, Germany.

Schmid has more than 15 years of experience in management consulting, marketing and sales.

Dude will be based in West Chester, PA. He has more than 20 years of experience in the IT services and software industries with Prime Technology Group, Glemser Technologies, First Consulting Group and Thomson Financial.

You may also like

Regulatory

AstraZeneca's New Drug Application for hypertension drug accepted under FDA Priority Review

Baxdrostat has had positive Phase III trial results and, if approved, could be the first aldosterone synthase inhibitor to receive regulatory authorisation
Regulatory

NOAH calls for Veterinary Medicines Agreement amid concerns over Northern Ireland veterinary medicines supply changes

With EU regulations set to apply fully from 1 January 2026, Northern Ireland could see 10-15% of veterinary medicines discontinued. Industry and government are working on mitigation schemes to protect animal health and ensure continued access to essential treatments
Regulatory

Piramal Pharma Solutions’ bioconjugates facility in Grangemouth, UK, receives updated MHRA GMP certificates

These certificates cover all activities conducted in the site’s Helix building, including its supporting warehouse and laboratory areas
Regulatory

UK-US pharma deal removes tariffs and boosts access to innovative medicines

The UK has secured a zero-tariff agreement on pharmaceutical exports to the US, alongside major reforms to accelerate NHS access to new treatments
Regulatory

EU approves Sanofi and Regeneron’s Dupixent as first targeted CSU treatment in more than a decade

The European Commission has authorised Dupixent for moderate-to-severe chronic spontaneous urticaria in patients aged 12+, offering the first new targeted option in more than ten years
Regulatory

FDA grants Medivir’s MIV-711 Orphan Drug Designation for Osteogenesis Imperfecta treatment

The FDA has awarded Orphan Drug Designation to Medivir’s selective cathepsin K inhibitor MIV-711 for Osteogenesis Imperfecta, a rare genetic bone disorder, after preclinical and clinical data suggests the therapy may strengthen bone
Regulatory

European Commission approves Teva denosumab biosimilars PONLIMSI and DEGEVMA

The two biosimilars to Prolia and Xgeva will expand access to important bone health treatments across Europe and bolster Teva's strong biosimilars portfolio
Subscribe now